StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

BioXcel Therapeutics's total debt was $104.45M at Jun 30, 2026. For fiscal 2025 it was $109.59M, up 6.9% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$109.59M+6.9%
FY2024Dec 31, 2024$102.51M+1.9%
FY2023Dec 31, 2023$100.60M+8.1%
FY2022Dec 31, 2022$93.05M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$104.45M-3.9%
Q1 FY2026Mar 31, 2026$100.29M-5.0%
Q4 FY2025Dec 31, 2025$109.59M+6.9%
Q3 FY2025Sep 30, 2025$109.13M+4.5%
Q2 FY2025Jun 30, 2025$108.69M+5.5%
Q1 FY2025Mar 31, 2025$105.53M+3.8%
Q4 FY2024Dec 31, 2024$102.51M+1.9%
Q3 FY2024Sep 30, 2024$104.44M+5.4%
Q2 FY2024Jun 30, 2024$103.01M+6.4%
Q1 FY2024Mar 31, 2024$101.63M+6.9%
Q4 FY2023Dec 31, 2023$100.60M+8.1%
Q3 FY2023Sep 30, 2023$99.09M+8.1%
Q2 FY2023Jun 30, 2023$96.85M+58.6%
Q1 FY2023Mar 31, 2023$95.06M–
Q4 FY2022Dec 31, 2022$93.05M–
Q3 FY2022Sep 30, 2022$91.70M–
Q2 FY2022Jun 30, 2022$61.08M–

More BioXcel Therapeutics figures

See a number that looks wrong?